NCT06251544View on ClinicalTrials.gov

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2034

Conditions
Breast CancerTumor, BreastBreast TumorMalignant Neoplasm of BreastMammary CancerMammary NeoplasmMammary Neoplasms, HumanNeoplasm, Breast
Interventions
GENETIC

HTR2 T Cells

"Arm A -- Two dose levels will be evaluated:~Dose level One: 1.00E+06~Dose level Two: 1.00E+07"

GENETIC

HTR2 T Cells

"Arm B -- Two dose levels will be evaluated:~Dose level Two: 1.00E+07~Dose Level Three: 1.00E+08"

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER